Urinary excretion of C5b-9 is associated with the anti-angiogenic state in severe preeclampsia

American Journal of Reproductive Immunology

Volumn 73, Issue 5, 2015, Pages 437-444

  Guseh, Stephanie H ^a   Feinberg, Bruce B ^b   Dawood, Hassan Y ^a   Yamamoto, Hidemi S ^a   Fichorova, Raina N ^a   Burwick, Richard M ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Department of Medicine   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Angiogenic proteins; C5b 9; Complement system proteins; Preeclampsia

Indexed keywords

ANGIOGENIC FACTOR; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; FIBROBLAST GROWTH FACTOR 2; PLACENTAL GROWTH FACTOR; VASCULOTROPIN; BIOLOGICAL MARKER; FLT1 PROTEIN, HUMAN; PLACENTA PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VEGFA PROTEIN, HUMAN;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GESTATIONAL AGE; HUMAN; HYPERTENSION; PREECLAMPSIA; PREGNANT WOMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; URINARY EXCRETION; URINE LEVEL; ADULT; CASE CONTROL STUDY; CLINICAL TRIAL; FOLLOW UP; PREGNANCY; URINE;

ADULT; BIOMARKERS; CASE-CONTROL STUDIES; COMPLEMENT MEMBRANE ATTACK COMPLEX; FEMALE; FIBROBLAST GROWTH FACTOR 2; FOLLOW-UP STUDIES; HUMANS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84927018816     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/aji.12349     Document Type: Article

References (49)

1. Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF: WHO analysis of causes of maternal death: a systematic review. Lancet 2006; 367:1066-1074.
2. Abalos E, Cuesta C, Carroli G, Qureshi Z, Widmer M, Vogel JP, Souza JP, on behalf of the WHO Multicountry Survey on Maternal and Newborn Health Research Network: Pre-eclampsia, eclampsia and adverse maternal and perinatal outcomes: a secondary analysis of the World Health Organization Multicountry Survey on Maternal and Newborn Health. BJOG 2014; 121(Suppl. 1):14-24.
3. Vigil-De Gracia P, Reyes Tejada O, Calle Minaca A, Tellez G, Chon VY, Herrarte E, Villar A, Ludmir J: Expectant management of severe preeclampsia remote from term: the MEXPRE Latin Study, a randomized multicenter clinical trial. Am J Obstet Gynecol 2013; 209:425.e1-425.e8.
4. Zuleta-Tobon JJ, Pandales-Perez H, Sanchez S, Velez-Alvarez GA, Velasquez-Penagos JA: Errors in the treatment of hypertensive disorders of pregnancy and their impact on maternal mortality. Int J Gynaecol Obstet 2013; 121:78-81.
5. Girardi G, Yarilin D, Thurman J, Holers V, Salmon J: Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med 2006; 203:2165-2175.
6. Qing X, Redecha PB, Burmeister MA, Tomlinson S, D'Agati VD, Davisson RL, Salmon JE: Targeted inhibition of complement activation prevents features of preeclampsia in mice. Kidney Int 2011; 79:331-339.
7. Wang W, Irani RA, Zhang Y, Ramin SM, Blackwell SC, Tao L, Kellems RE, Xia Y: Autoantibody-mediated complement C3a receptor activation contributes to the pathogenesis of preeclampsia. Hypertension 2012; 60:712-721.
8. Salmon J, Heuser C, Triebwasser M, Liszewski M, Kavanagh D, Roumenina L, Branch DW, Goodship T, Fremeaux-Bacchi V, Atkinson JP: Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med 2011; 8:e1001013.
9. Fang C, Fremeaux-Bacchi V, Liszewski M, Pianetti G, Noris M, Goodship T, Atkinson JP: Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood 2008; 111:624-632.
10. Lynch A, Gibbs R, Murphy J, Giclas P, Salmon J, Holers V: Early elevations of the complement activation fragment C3a and adverse pregnancy outcomes. Obstet Gynecol 2011; 117:75-83.
11. Lynch A, Eckel R, Murphy J, Gibbs R, West N, Giclas P, Salmon JE, Holers VM: Prepregnancy obesity and complement system activation in early pregnancy and the subsequent development of preeclampsia. Am J Obstet Gynecol 2012; 206:428.e1-428.e8.
12. Burwick R, Feinberg B: Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta 2013; 34:201-203.
13. Richani K, Soto E, Romero R, Espinoza J, Chaiworapongsa T, Nien JK, Edwin SS, Kim YM, Hong JS, Goncalves LF, Yeo L, Mazor M, Hassan SS, Kusanovic JP: Normal pregnancy is characterized by systemic activation of the complement system. J Matern Fetal Neonatal Med 2005; 17:239-245.
14. Haeger M, Unander M, Andersson B, Tarkowski A, Arnestad JP, Bengtsson A: Increased release of tumor necrosis factor alpha and interleukin-6 in women with the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Acta Obstet Gynecol Scand 1996; 75:695-701.
15. Burwick RM, Fichorova RN, Dawood HY, Yamamoto HS, Feinberg BB: Urinary excretion of C5b-9 in severe preeclampsia: tipping the balance of complement activation in pregnancy. Hypertension 2013; 62:1040-1045.
16. de Messias-Reason IJ, Aleixo V, de Freitas H, Nisihara RM, Mocelin V, Urbanetz A: Complement activation in Brazilian patients with preeclampsia. J Investig Allergol Clin Immunol 2000; 10:209-214.
17. Derzsy Z, Prohaszka Z, Rigo J, Fust G, Molvarec A: Activation of the complement system in normal pregnancy and preeclampsia. Mol Immunol 2010; 47:1500-1506.
18. Denny KJ, Coulthard LG, Finnell RH, Callaway LK, Taylor SM, Woodruff TM: Elevated complement factor C5a in maternal and umbilical cord plasma in preeclampsia. J Reprod Immunol 2013; 97:211-216.
19. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111:649-658.
20. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA: Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350:672-683.
21. Shibata E, Rajakumar A, Powers RW, Larkin RW, Gilmour C, Bodnar LM, Crombleholme WR, Ness RB, Roberts JM, Hubel CA: Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab 2005; 90:4895-4903.
22. Kim SY, Ryu HM, Yang JH, Kim MY, Han JY, Kim JO, Chung JH, Park SY, Lee MH, Kim DJ: Increased sFlt-1 to PlGF ratio in women who subsequently develop preeclampsia. J Korean Med Sci 2007; 22:873-877.
23. De Vivo A, Baviera G, Giordano D, Todarello G, Corrado F, D'anna R: Endoglin, PlGF and sFlt-1 as markers of predicting preeclampsia. Acta Obstet Gynecol Scand 2008; 87:837-842.
24. Kendall RL, Thomas KA: Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993; 90:10705-10709.
25. Kendall RL, Wang G, DiSalvo J, Thomas KA: Specificity of vascular endothelial growth factor receptor ligand binding domains. Biochem Biophys Res Commun 1994; 201:326-330.
26. Clark DE, Smith SK, Sharkey AM, Charnock-Jones DS: Localization of VEGF and expression of its receptors flt and KDR in human placenta throughout pregnancy. Hum Reprod 1996; 11:1090-1098.
27. Clark DE, Smith SK, He Y, Day KA, Licence DR, Corps AN, Lammoglia R, Charnock-Jones DS: A vascular endothelial growth factor antagonist is produced by the human placenta and released into maternal circulation. Biol Reprod 1998; 59:1540-1548.
28. Lynch AM, Murphy JR, Gibbs RS, Levine RJ, Giclas PC, Salmon JE, Holers VM: The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. BJOG 2010; 117:456-462.
29. Boij R, Svensson J, Nilsson-Ekdahl K, Sandholm K, Lindahl TL, Palonek E, Garle M, Berg G, Ernerudh J, Jenmalm M, Matthiesen L: Biomarkers of coagulation, inflammation, and angiogenesis are independently associated with preeclampsia. Am J Reprod Immunol 2012; 68:258-270.
30. ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin: Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002; 99:159-167.
31. Langer HF, Chung KJ, Orlova VV, Choi EY, Kaul S, Kruhlak MJ, Alatsatianos M, DeAngelis RA, Roche PA, Magotti P, Li X, Economopoulou M, Rafail S, Lambris JD, Chavakis T: Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis. Blood 2010; 116:4395-4403.
32. Conroy AL, Silver KL, Zhong K, Rennie M, Ward P, Sarma JV, Molyneux ME, Sled J, Fletcher JF, Rogerson S, Kain KC: Complement activation and the resulting placental vascular insufficiency drives fetal growth restriction associated with placental malaria. Cell Host Microbe 2013; 13:215-226.
33. Burwick RM, Easter SR, Dawood HY, Yamamoto HS, Feinberg BB: Complement activation and kidney injury molecule-1-associated proximal tubule injury in severe preeclampsia. Hypertension 2014; 64:833-838.
34. Gekle M: Renal tubule albumin transport. Annu Rev Physiol 2005; 67:573-594.
35. Peng Q, Li K, Smyth LA, Xing G, Wang N, Meader L: C3a and C5a promote renal ischemia-reperfusion injury. J Am Soc Nephrol 2012; 23:1474-1485.
36. Zhou W, Farrar CA, Abe K, Pratt JR, Marsh JE, Wang Y, Stahl GL, Sacks SH: Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 2000; 105:1363-1371.
37. Riddell MR, Winkler-Lowen B, Chakrabarti S, Dunk C, Davidge ST, Guilbert LJ: The characterization of fibrocyte-like cells: a novel fibroblastic cell of the placenta. Placenta 2012; 33:143-150.
38. Schlembach D, Wallner W, Sengenberger R, Stiegler E, Mortl M, Beckmann MW, Lang U: Angiogenic growth factor levels in maternal and fetal blood: correlation with Doppler ultrasound parameters in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 2007; 29:407-413.
39. Major HD, Campbell RA, Silver RM, Branch DW, Weyrich AS: Synthesis of sFlt-1 by platelet-monocyte aggregates contributes to the pathogenesis of preeclampsia. Am J Obstet Gynecol 2014; 210:547.e1-547.e7.
40. Kalkunte SS, Neubeck S, Norris WE, Cheng SB, Kostadinov S, Vu Hoang D, Ahmed A, von Eggeling F, Shaikh Z, Padbury J, Berg G, Olofsson A, Markert UR, Sharma S: Transthyretin is dysregulated in preeclampsia, and its native form prevents the onset of disease in a preclinical mouse model. Am J Pathol 2013; 183:1425-1436.
41. Oppermann M, Gotze O: Plasma clearance of the human C5a anaphylatoxin by binding to leucocyte C5a receptors. Immunology 1994; 82:516-521.
42. Kerjaschki D, Schulze M, Binder S, Kain R, Ojha PP, Susani M, Horvat R, Baker PJ, Couser WG: Transcellular transport and membrane insertion of the C5b-9 membrane attack complex of complement by glomerular epithelial cells in experimental membranous nephropathy. J Immunol 1989; 143:546-552.
43. Lillegard KE, Johnson AC, Lojovich SJ, Bauer AJ, Marsh HC, Gilbert JS, Regal JF: Complement activation is critical for placental ischemia-induced hypertension in the rat. Mol Immunol 2013; 56:91-97.
44. Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B, Bruckner UB, Nilsson B, Gebhard F, Lambris JD, Huber-Lang M: Molecular intercommunication between the complement and coagulation systems. J Immunol 2010; 185:5628-5636.
45. Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR, Lambris JD, Warner RL, Flierl MA, Hoesel LM, Gebhard F, Younger JG, Drouin SM, Wetsel RA, Ward PA: Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006; 12:682-687.
46. Shulze M, Donadio JV, Pruchno CJ, Baker PJ, Johnson RJ, Stahl RAK, Watkins S, Martin DC, Wurzner R, Gotze O: Elevated urinary excretion of the C5b-9 complex in membranous nephropathy. Kidney Int 1991; 40:533-538.
47. van der Pol P, de Vries DK, van Gijlswijk DJ, van Anken GE, Schlagwein N, Daha MR, Aydin Z, de Fijter JW, Schaapherder AF, van Kooten C: Pitfalls in urinary complement measurements. Transpl Immunol 2012; 27:55-58.
48. Morita Y, Ikeguchi H, Nakamura J, Hotta N, Yuzawa Y, Matsuo S: Complement activation products in the urine from proteinuric patients. J Am Soc Nephrol 2000; 11:700-707.
49. Lehto T, Honkanen E, Teppo AM, Meri S: Urinary excretion of protectin (CD59), complement SC5b-9 and cytokines in membranous glomerulonephritis. Kidney Int 1995; 47:1403-1411.